Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustheartcellsubjectcardiac
  Phrases that lowered it: myelomaparticipantsmalelightmultiple
• Sponsor's past termination rate: 28.6% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor's past trials: 448 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 169 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 95.8% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 29.5% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 42822 (lowers risk) · Drug's FDA history
• Keywords listed: 10 (lowers risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis NCT01570387 · started 2012 · scored riskier than 78% of active trials completed
• First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD NCT01728259 · started 2013 · scored riskier than 94% of active trials terminated
• A Trial for Systemic Light-chain (AL) Amyloidosis NCT01277016 · started 2011 · scored riskier than 79% of active trials completed
• Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis NCT04895917 · started 2021 · scored riskier than 77% of active trials terminated
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis NCT01072773 · started 2010 · scored riskier than 88% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.